Regeneron Pharmaceuticals Inc
REGNRegeneron Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing innovative medicines for serious medical conditions. Founded in 1988, it specializes in monoclonal antibody technologies and has a broad pipeline targeting areas such as ophthalmology, oncology, immunology, and infectious diseases. Known for its collaborations and investment in scientific research, Regeneron has contributed significantly to the development of treatments for various diseases.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 5, 2025 | $0.88 | 2025-11-20 | 2025-11-20 |
| September 3, 2025 | $0.88 | 2025-08-18 | 2025-08-18 |
| June 6, 2025 | $0.88 | 2025-05-20 | 2025-05-20 |
| March 20, 2025 | $0.88 | 2025-02-20 | 2025-02-20 |
Dividends Summary
- Regeneron Pharmaceuticals Inc has issued 4 dividend payments over the past 0 years
- The most recent dividend was paid 32 days ago, on December 5, 2025
- The highest dividend payed out to investors during this period was $0.88 per share
- The average dividend paid during this period was $0.88 per share.
Company News
Regeneron is addressing competition challenges for its Eylea drug and developing promising new therapies, including potential treatments for muscle mass maintenance and hearing loss, which could boost its financial performance.
Tessera Therapeutics presented promising preclinical data at the ASH Annual Meeting, demonstrating significant progress in Gene Writing technology for sickle cell disease and T cell therapies, with successful in vivo editing of long-term hematopoietic stem cells and generation of functional CAR-T cells in non-human primates.
CRISPR Therapeutics reported positive Phase 1 trial results for CTX310, an investigational gene therapy targeting ANGPTL3, demonstrating significant lipid-lowering effects with a single treatment and no serious adverse events.
With US markets recovering and Q3 earnings approaching, three potentially undervalued stocks show promise: Comcast, Regeneron Pharmaceuticals, and Arch Capital Group, each presenting unique investment opportunities based on technical and fundamental analysis.
Regeneron Pharmaceuticals reported better-than-expected Q2 results, driven by growth in Eylea HD, Dupixent, and Libtayo. However, Eylea sales declined due to increased competition. The company's pipeline progress was mixed, with a delay in the FDA decision for linvoseltamab and a three-month extension for the Dupixent COPD indication.
